Exhibiting at VIV Asia 2025

Optipharm Co., Ltd., headquartered in Cheongju-si, South Korea, is a pioneering biotechnology and pharmaceutical company specializing in veterinary diagnostics, biopharmaceuticals, and advanced disease prevention solutions. Since its founding, Optipharm has developed a strong reputation in both animal and human health sectors by leveraging advanced research in bacteriophages, virus-like particle (VLP) vaccines, and xenotransplantation.

Core Business and Offerings

Optipharm’s diverse product and service offerings are rooted in its commitment to science-based healthcare innovation. The company’s primary business areas include:

• Animal Disease Diagnostic Services

  • Comprehensive livestock disease appraisal services
  • Serological, molecular, and microbiological analysis
  • Surveillance for swine fever, avian influenza, and foot-and-mouth disease (FMD)

• Veterinary Pharmaceuticals

  • Animal-specific antibiotics, feed additives, and immunostimulants
  • Preventive and therapeutic agents tailored for the swine and poultry industries

• Bacteriophage Products

  • Highly targeted phage therapies to replace or reduce antibiotics
  • Addressing pathogens such as E. coli, Salmonella, and Clostridium perfringens

• Virus-Like Particle (VLP) Vaccines

  • Cutting-edge VLP-based vaccines for both veterinary and human applications
  • Designed to offer high immunogenicity without using infectious viruses

• Xenotransplantation Products

  • Development of genetically engineered xenogeneic organs and tissues
  • Aimed at future applications in human transplantation and regenerative medicine

• Human Diagnostic Kits

  • Rapid diagnostic test kits for early detection of diseases such as breast cancer, cervical cancer, and COVID-19
  • CE-certified kits with potential for global distribution

Specialisation and Unique Selling Proposition (USP)

Optipharm’s core strength lies in its multi-disciplinary integration of biotechnology, diagnostics, and pharmacology. Key differentiators include:

• Advanced bacteriophage R&D capability, one of the few in Asia
• First mover in VLP vaccine development in South Korea for animal health
• Integration of diagnostics and therapeutics for precision veterinary medicine
• Global potential of xenotransplantation research pipeline

Its strategic focus on post-antibiotic era solutions, such as phage therapy and precision diagnostics, uniquely positions it within the evolving global biohealth market.

Financials and Market Presence

Optipharm Co., Ltd. is a publicly listed company on the Korean New Exchange (KONEX). As per the latest filings:

• Annual revenue has crossed KRW 30 billion (~USD 25 million)
• R&D investment accounts for over 12% of annual turnover, demonstrating a deep commitment to innovation
• The company exports products and diagnostic services to over 10 countries, primarily in Asia

Its revenue mix spans veterinary diagnostics (~40%), veterinary pharmaceuticals (~35%), and biotech pipeline projects (~25%).

Export and International Collaboration

Optipharm collaborates with international research institutions and commercial partners to extend its reach beyond South Korea. Highlights include:

• Exports of animal diagnostics and bacteriophage products to Japan, Vietnam, and China
• CE certification for several human diagnostic kits, enabling distribution in Europe
• Active research collaboration with universities in Europe and the U.S. on xenotransplantation and VLP vaccine platforms

The company also participates in major industry exhibitions such as VIV Asia, BioKorea, and Animal Health Innovation Asia.

Target Markets

Optipharm targets a wide range of markets in both animal and human health sectors:

• Veterinary Clinics and Animal Hospitals
• Commercial Livestock Producers (poultry, swine, ruminants)
• Feed Mill Integrators and Distributors
• Government Disease Surveillance Programs
• Biopharma and Human Health Diagnostic Distributors
• Academic and Research Institutions

The company provides both off-the-shelf and tailored solutions for diagnostics, disease prevention, and therapeutics.

Capabilities

• ISO-certified laboratories and GMP manufacturing
• Fully equipped phage and molecular biology research facilities
• High-throughput diagnostic testing capacity for animal health programs
• Regulatory support and documentation for global product registration
• AI and software integration in disease monitoring and early warning systems

Their team includes veterinary pathologists, microbiologists, and biotech engineers, enabling full-spectrum development from lab to field.

Certifications and Compliance

Optipharm adheres to the highest quality and safety standards, including:

• ISO 9001 and ISO 13485 for medical devices and diagnostics
• GMP-compliant pharmaceutical production for veterinary products
• CE Marking for human diagnostic kits
• KFDA (Korean Food and Drug Administration) approval for all domestically sold products
• Ongoing GLP (Good Laboratory Practice) compliance for trials and testing

These standards ensure reliability for public health institutions, distributors, and animal health providers alike.

Customer Feedback and Recognition

Optipharm products and services are widely used by livestock producers and veterinary authorities, who report:

• High sensitivity and specificity in diagnostics, reducing disease mismanagement
• Improved animal growth performance and mortality reduction using bacteriophage products
• Compliance with international antibiotic-reduction standards

Academic endorsements and third-party trial data further validate the effectiveness of its proprietary solutions.

Major Achievements

• Pioneer in bacteriophage development for veterinary applications in South Korea
• Launched the first VLP-based veterinary vaccine prototypes in domestic markets
• Developed COVID-19 antigen test kits exported to multiple countries during the pandemic
• Recognized as a top biotech innovator by the Ministry of Agriculture and Rural Development
• Continued listing and growth on KONEX exchange, with strong investor interest in biotech portfolio

Optipharm Co., Ltd. stands at the forefront of biotech innovation in Asia, offering solutions that merge diagnostics, pharmaceuticals, and next-gen biotech platforms for healthier animals and safer food systems—while expanding its impact on human health through precision diagnostics and regenerative medicine research.